Schuman Joel S
New England Eye Center, Tufts-New England Medical Center, Tufts University School of Medicine, 750 Washington Street, Box 450, Boston, MA 02111, USA.
Expert Opin Drug Saf. 2002 Jul;1(2):181-94. doi: 10.1517/14740338.1.2.181.
Glaucoma, a leading cause of blindness worldwide, is a chronic neurodegenerative disorder. Patients with glaucoma may require long-term administration of intraocular pressure (IOP)-lowering medications. These medications belong to several classes of molecules including beta-adrenergic blockers, cholinergic agents, alpha-adrenergic agonists, carbonic anhydrase inhibitors and ocular hypotensive lipids. Most adverse effects associated with IOP-lowering medications are mild and ocular in nature; however, several of them are associated with systemic risks as well as serious ocular effects, especially following chronic use. The following review discusses the acute and long-term effects of commonly used IOP-lowering medications.
青光眼是全球失明的主要原因之一,是一种慢性神经退行性疾病。青光眼患者可能需要长期使用降低眼压(IOP)的药物。这些药物属于几类分子,包括β-肾上腺素能阻滞剂、胆碱能药物、α-肾上腺素能激动剂、碳酸酐酶抑制剂和降眼压脂质。与降低眼压药物相关的大多数不良反应性质轻微且局限于眼部;然而,其中一些也与全身风险以及严重的眼部影响有关,尤其是在长期使用后。以下综述讨论了常用降低眼压药物的急性和长期影响。